Education
About Us
Working with TipRanks
Follow Us
Roche Holding (GB:0QOK)
:0QOK
0QOK Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF212.30 - CHF313.70
Previous CloseN/A
Volume341.09K
Average Volume (3M)721.70K
Market Cap
CHF235.70B
Enterprise ValueCHF228.34B
Total Cash (Recent Filing)CHF1.84B
Total Debt (Recent Filing)CHF30.06B
Price to Earnings (P/E)28.2
Beta0.56
Next Earnings
Jul 24, 2025EPS Estimate
10.64Last Dividend Ex-Date
Mar 27, 2025Dividend Yield3.38%
Share Statistics
EPS (TTM)10.39
Shares Outstanding702,562,700
10 Day Avg. Volume850,286
30 Day Avg. Volume721,699
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF285.43Price Target Upside3.34% Upside
Rating ConsensusHold
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsRoche will deliver a substantial number of clinical readouts which can decide a turnaround to the story.
Sales PotentialThree potential assets, each forecasted to generate over $5bn in sales, have been highlighted, with Giredestrant for 1L breast cancer showing the highest conviction.
Bears Say
Competition And SafetyData have not shown a clear benefit vs competition and safety, in particular, does not seem to provide any advantage.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
10.03%
Mutual Funds
0.04% Other Institutional Investors
79.66% Public Companies and
Individual Investors
0QOK FAQ
What was Roche Holding’s price range in the past 12 months?
Roche Holding lowest share price was CHF212.30 and its highest was CHF313.70 in the past 12 months.
What is Roche Holding’s market cap?
Roche Holding’s market cap is CHF235.70B.
When is Roche Holding’s upcoming earnings report date?
Roche Holding’s upcoming earnings report date is Jul 24, 2025 which is in 111 days.
How were Roche Holding’s earnings last quarter?
Roche Holding released its earnings results on Jan 30, 2025. The company reported CHF8.57 earnings per share for the quarter, beating the consensus estimate of CHF8.12 by CHF0.45.
Is Roche Holding overvalued?
According to Wall Street analysts Roche Holding’s price is currently Undervalued.
Does Roche Holding pay dividends?
Roche Holding pays a Annually dividend of CHF9.699 which represents an annual dividend yield of 3.38%. See more information on Roche Holding dividends here
What is Roche Holding’s EPS estimate?
Roche Holding’s EPS estimate is 10.64.
How many shares outstanding does Roche Holding have?
Roche Holding has 702,562,700 shares outstanding.
What happened to Roche Holding’s price movement after its last earnings report?
Roche Holding reported an EPS of CHF8.57 in its last earnings report, beating expectations of CHF8.12. Following the earnings report the stock price went up 0.673%.
Which hedge fund is a major shareholder of Roche Holding?
Currently, no hedge funds are holding shares in GB:0QOK
---
Company Description
Roche Holding
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
---
0QOK Company Deck
---
0QOK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Roche demonstrated strong financial performance in 2024 with significant growth in sales, operating profit, and cash flow. The pharmaceutical and diagnostics divisions both showed robust growth, supported by strategic acquisitions and new product launches. However, challenges such as the decline in COVID-19 sales, impairments affecting net income, and market challenges in China were notable concerns. Overall, the highlights substantially outweigh the lowlights.Read More>---
0QOK Stock 12 Month Forecast
Average Price Target
CHF285.43
▲(3.34% Upside)
Technical Analysis
Best Analysts Covering 0QOK
1 Year
1 Year Success Rate
27/46 ratings generated profit
1 Year Average Return
+1.68%
reiterated a sell rating yesterday
Copying Richard Vosser's trades and holding each position for 1 Year would result in 58.70% of your transactions generating a profit, with an average return of +1.68% per trade.
---